title: Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response.
abstract: Src tyrosine kinases regulate a large number of important mechanisms in normal and cancerous cells, are overexpressed in a broad range of tumors including lung cancer, and thus represent a potential target for cancer therapy. Preclinical experiments indicate that small-molecule inhibitors of Src block tumor growth, metastasis, and angiogenesis. Phase I data from healthy volunteers also suggest that inhibitors of Src prevent bone resorption. Several phase II trials with small-molecule inhibitors of Src are under way or have been initiated in lung cancer and in other malignancies, as discussed herein.
authors.affiliation: Department of Cardiothoracic Surgery, Stanford University School of Medicine, CA 94303, USA. jsd@stanford.edu
authors.forename: Jessica S
authors.initials: JS
authors.lastname: Donington
authors.forename: Quynh-Thu
authors.initials: QT
authors.lastname: Le
authors.forename: Heather A
authors.initials: HA
authors.lastname: Wakelee
mesh_terms: D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000209:etiology / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D008297:Male; D012306:Risk; D012307:Risk Factors; D017678:Sex Distribution; D012907:Smoking / Q000009:adverse effects; D015996:Survival Rate